Rigel Pharmaceuticals, Inc. Quarterly report [Sections 13 or 15(d)]

NET INCOME (LOSS) PER SHARE (Tables)

6 Months Ended

Jun. 30, 2025


	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
EPS Numerator:
Net income (loss)	$	59,613	$	(1,030)	$	71,059	$	(9,277)
EPS Denominator—Basic:
Weighted-average common shares outstanding		17,885		17,549		17,848		17,534
EPS Denominator—Diluted:
Weighted-average common shares outstanding		17,885		17,549		17,848		17,534
Dilutive effect of stock options, RSUs and shares under Purchase Plan		277		—		320		—
Weighted-average shares outstanding and common stock equivalents		18,162		17,549		18,168		17,534

Net income (loss) per share
Basic	$	3.33	$	(0.06)	$	3.98	$	(0.53)
Diluted	$	3.28	$	(0.06)	$	3.91	$	(0.53)